Al Harbi Adel S
Department of Pediatric Pulmonary Medicine, Prince Sultan Military Medical City, Riyadh, Kingdom of Saudi Arabia. E-mail.
Saudi Med J. 2018 Dec;39(12):1200-1206. doi: 10.15537/smj.2018.12.23355.
To assess the respiratory syncytial virus (RSV) infection incidence rate through the analysis of data collected before and after implementation of a new palivizumab dosing regimen customized for a high-risk Saudi population. Methods: This was a retrospective cohort study performed at Prince Sultan Military Medical City, Riyadh, Saudi Arabia between November 2009 and April 2017 on 1704 high risk Saudi young children and comparing 3 palivizumab regimens: a 4-week interval dosing regimen starting in either November or mid-September and a 3-week interval dosing regimen starting in mid-September. Results: Despite a decrease in the incidence rate of RSV infection with the three-week interval regimen (3.9% versus 5.9% in seasons 1 and 9.1% in seasons 2), we did not find significant differences among the 3 groups. Conclusion: Expanded use of palivizumab in newborn children could improve outcomes, but further investigation and a careful cost analysis are required.
通过分析为沙特高危人群定制的新帕利珠单抗给药方案实施前后收集的数据，评估呼吸道合胞病毒（RSV）感染发病率。方法：这是一项回顾性队列研究，于2009年11月至2017年4月在沙特阿拉伯利雅得的苏丹王子军事医疗城对1704名沙特高危幼儿进行，比较3种帕利珠单抗给药方案：从11月或9月中旬开始的4周间隔给药方案，以及从9月中旬开始的3周间隔给药方案。结果：尽管三周间隔方案使RSV感染发病率有所下降（第1季为3.9%，而第1季为5.9%，第2季为9.1%），但我们未发现3组之间存在显著差异。结论：扩大帕利珠单抗在新生儿中的使用可能会改善治疗效果，但需要进一步研究和仔细的成本分析。
